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Resum
L’obtenció de nous materials micro– i nanoestructurats, i la
possibilitat de manipular materials ja existents a escala
nanoscòpica, tenen un paper crucial en els avenços assolits
durant els darrers anys dins del món farmacèutic i de la diag-
nosi clínica. Dins d’aquest context s’ha observat que els pro-
gressos en la preparació de materials amb propietats excep-
cionals derivades de la seva estructura nanoscòpica, com ara
les nanoesferes, les nanosuspensions, els materials compos-
tos nanoparticulats, etc., poden contribuir molt significativa-
ment a reduir la toxicitat de fàrmacs i agents de contrast, aug-
mentar-ne l’absorció i fer més eficient el perfil de lliurament del
principi actiu. Ara bé, per a poder explotar comercialment
l’enorme potencial de les nanomedicines és necessari dis-
senyar i desenvolupar tecnologies eficients i respectuoses amb
el medi ambient, que permetin obtenir, a escala industrial,
aquests materials farmacèutics micro– i nanoestructurats. 
En aquesta revisió, pretenem donar a conèixer diferents
mètodes de precipitació, recentment desenvolupats, els quals
permeten obtenir directament materials micro– i nanoparticu-
lats. En aquests procediments, en lloc de dissolvents orgànics
nocius per a les persones i el medi ambient, s’empren fluids
comprimits com a medi dissolvent, els quals estan considerats
dissolvents verds. A més a més, aquests mètodes de
preparació permeten l’obtenció de materials amb una estruc-
tura interna (polimorfisme, porositat, etc.) que no és possible
d’assolir mitjançant procediments de preparació realitzats en
dissolvents líquids convencionals.
Abstract
Obtaining new micro– and nanostructured molecular materials,
and understanding how to manipulate existing materials at the
nanoscopic level, is crucial to the development of drug delivery
and clinical diagnostics. Advances in the preparation of materi-
als characterised by exceptional properties attributable to their
nanoscopic structure, such as nanosuspensions, nanos-
pheres, nanoparticulate composites, etc., can significantly
contribute to reducing the toxicity of drugs and contrast
agents, increase their absorption, and improve their release
profile. However, in order to be able to exploit the enormous
potential of these nanomedicines, it is necessary to develop ef-
ficient and environmentally respectful technologies for its man-
ufacture at an industrial scale. In this review, we endeavour to
present various recent eco-efficient precipitation procedures,
which have been proved to be effective for the straightforward
preparation of micro– and nanoparticulate materials. In these
procedures, instead of hazardous organic solvents, «green»
compressed fluids are used as solvent media, which allow the
preparation of materials with physico-chemical characteristics
unachievable by conventional procedures performed in con-
ventional liquid media.
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From an esthetical perspective, it is attractive to build all desir-
able pharmacological features of a drug or a diagnostic agent -
such as solubility, permeability to biological membranes, and
targeting towards particular tissues, cells, and intramolecular
compartments – into the drug or the diagnostic agent molecule
itself. However, it is simpler and perhaps more powerful to ob-
tain these features by decoupling the biological action from the
other biochemical and physicochemical characteristics that
determine such key features of their pharmacology [1]. Follow-
ing this strategy, during the past two decades, it has been ob-
served that advances in the preparation of materials charac-
terised by exceptional properties attributable to their
nanoscopic structure, can significantly contribute to the devel-
opment of new drug delivery routes, of more selective and effi-
cient disease-detection systems, and to the preparation of
pharmaceuticals with a higher permeability to biological mem-
branes, with controlled release profiles and with enhanced tar-
geting towards particular tissues or cells, combining diagnostic
and therapeutic actions for instantaneous administration of
therapy [2, 3]. 
For example, a surprisingly large proportion of new drug
candidates emerging from drug discovery programmes are
water insoluble, and therefore have poor bioavailability, which
often leads to development being abandoned. These so-called
«brick-dust» candidates can now be rescued by formulating
them into crystalline nanosuspensions [4]. Nanosuspensions
overcome delivery issues by obviating the need to be dis-
solved, and maintaining the drug in the preferred crystalline
state, at a size small enough for pharmaceutical acceptability.
In addition to overcoming issues of solubility, nanosuspensions
have shown additional benefits. For example, nanosuspen-
sions enable a higher mass per volume loading in comparison
to solutions, allowing reduced administration volumes, which is
crucial for low-volume intramuscular and ophthalmic applica-
tions [5]. On the other hand, the particulate nature of the
dosage form might offer alternative pharmacokinetic profiles;
both in intravenous delivery, where one might expect lower
toxicity and more efficacious regimens, and in oral delivery,
where we might find potential for first-pass hepatic metabo-
lism. 
Similarly, the use of nanoparticles (particles with dimensions
in the range of 10nm to a few hundred nanometers), is gaining
momentum in drug delivery and diagnostic imaging. Emul-
sions and liposomes are perhaps better-known particulate
carriers with comparatively long histories of research. Recent-
ly, various other types of nanoparticles have been investigated
in the search for alternative carriers. Most of those carriers ac-
cumulate to the target site during continuous systemic circula-
tion, delivering the drug substance thereon: so-called «passive
targeting», the behaviour of which depends highly upon
physicochemical characteristics. However, much effort has
been made to achieve «active targeting», delivering drugs
more actively to the target site by utilizing specific physical
forces such as magnetic attraction or biochemical interactions
(such as receptor-ligands or antigen-antibody interactions).
The application of micro– and nanoscale polymer particles and
spheres in therapeutic systems has been well documented,
and various systems have been designed for intelligent modu-
lated delivery [6,7,8]. The incorporation of therapeutic and di-
agnostic pharmaceuticals to these nanoparticulate carriers
might lead to advantages such as increased water solubility of
sparingly soluble agents, enhanced permeability across physi-
ological barriers, substantial changes in drug distribution, in-
creased bioavailability and reduction of adverse side effects.
For example, self assembled core/shell spherical aggregates
of block copolymers recently emerged as a possible alterna-
tive to liposomes as carriers of drugs and diagnostic agents
(Figure 1).
Davis and Illum have conducted extensive investigations
on biodegradable nanospheres with polylactides and
poly(lactide-co-glycolide) as carriers for achieving the effi-
cient delivery of drugs and diagnostic agents to the lymphat-
ic system. To enhance lymphatic drainage and lymphatic
node uptake of nanospheres, various surface engineering
methods have been tried, including surface coating with
poloxamides or poloxamers [9] and the use of polyethyleng-
lycols [10]. Besides the drug delivery purpose, magnetite-
dextran nanoparticles have been investigated for diagnostic
use and found potentially useful as contrast agents in mag-
netic resonance imaging [11]. Wang and co. have reported a
new strategy for amplifying electrical DNA sensing based on
the use of microsphere tags loaded internally with a «redox
marker». Such electroactive beads offer great potential for
multitarget detection (in connection to spheres loaded with
different redox markers) and for enhancing the sensitivity of
other bioassays [12].
However in order to be able to commercially exploit the
enormous potential of nanomedicines such as the ones de-
scribed above, it is necessary the development of efficient
technologies for the manufacture of these contaminant-free
nanostructured materials, at an industrial scale, in an environ-
mentally responsible manner. Presently, the different methods
for the preparation of nanoparticulate materials can be divided
into two main categories: «top-down» strategies where the raw
material is subsequently broken down using physical methods
(i.e. dry or wet milling) until nanoscopic dimensions are
reached; and «bottom-up» approaches where nanomaterials
are built from their constituent units (polymers, macromole-
cules, molecules, atoms) by synthetic or self-assembly proce-
dures. 
Figure 1. Individual block-copolymers can self-assemble into
nanoparticles with a hydrophobic core and hydrophilic corona. The
drug is selectively loaded into the core, and the corona protects it until
its delivery.
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The potential of «bottom-up» strategies for material engi-
neering is much larger than that of «top-down» approaches. As
Feynman put it, very simply, «What would the properties of ma-
terials be if we could arrange the atoms and molecules the way
we want them?» [13]. Such a dream, up till now, remains unful-
filled in general, at least in terms of molecular self-assembly in
the crystalline state. Through «bottom-up» technologies it
should be possible to design and control particle size and size
distribution, morphology and the internal structure of the final
nanoparticulate material, whereas using «top-down» proce-
dures we can only control the final particle size, whilst the inter-
nal structure of the raw material cannot be modified, and it is
very difficult to govern the particle morphology. 
In any «bottom-up» process involving precipitation from so-
lution, particle size, particle size distribution, morphology, and
internal structure (polymorphs, solvates, etc.) are strongly de-
pendent on the evolution during the precipitation process of
the supersaturation rate (β ), which drives nucleation rate and
crystal growth, at each point in the solution [14]. For instance,
in those precipitation processes where large levels of supersat-
uration are attained rapidly (trace A of Figure 3), and where
there is a high homogeneity of this supersaturation profile
throughout the bulk solution, nucleation phenomena will domi-
nate crystal growth, and very small and essentially monodis-
perse particles will be produced. On the contrary, in those pre-
cipitation processes with a β profile more comparable to trace
B of Figure 3, the solute in solution is depleted by both nucle-
ation and crystal growth mechanisms resulting in large crystals
being formed, with a broad particle size distribution.
Again different are those precipitation processes occurring
far from equilibrium conditions, where large β values are at-
tained over short periods of time –allowing the preparation of
internal structures favoured by kinetic factors rather than ther-
modynamic ones. In contrast, in those precipitation processes
which take place near equilibrium conditions, thermodynami-
cally stable internal structures are more likely. 
In processes involving precipitation from conventional liq-
uid solvents, supersaturation is generally triggered by temper-
ature or system composition changes (e.g. solvent evapora-
tion, addition of anti-solvents, addition of salts). By using such
solvent-based precipitation processes, it is very difficult to
straightforward produce micro– and nanoparticulate materi-
als, since temperature and composition variations are only
slowly transmitted in liquid media, and efficient and expensive
stirring systems are required in order to achieve large values
of β homogeneously. Thus, additional downstream opera-
tions, such as milling and sieving, are required to achieve the
desired particle size.
In contrast with liquid solvents, the solvent power of com-
pressed fluids (CFs), either in the liquid or supercritical state,
can be tuned by pressure changes, which propagate much
more quickly than temperature and composition solvent
changes. Therefore, using compressed solvent media, it is of-
ten possible to synthesize materials with unique physico-
chemical characteristics (size, porosity, polymorphic nature,
morphology, etc.) unachievable with classical liquid media [15,
16]. CFs are substances that exist as a single phase, and offer
several advantages over both liquids and gases. CFs often
have liquid-like densities and, hence, solvating characteristics
that are similar to those of liquids, but mass transfer properties
that are more similar to those of gases. Small changes in tem-
perature and pressure result in large changes in the fluid’s den-
sity, and hence, its solvent power. This tuneable range in den-
sity (solvation ability) cannot be achieved so easily with any
conventional solvent. The most widely used CF is compressed
CO2 (cCO2), which is non-toxic, non-flammable, cheap and
easy recyclable. It has gained considerable attention, during
the past few years as a «green substitute» to organic solvents
and even water in industrial processing. During the past two
decades, «bottom-up» approaches using cCO2 as a solvent
medium have attracted scientific and technological interest for
the preparation of nanostructured materials (particles, fibres,
templates, porous materials, etc.) [17] . The use of cCO2 as a
solvent medium for fine particle formation is an active research
field, in which considerable technological development is ex-
pected [18]. In these «green» precipitation processes with
cCO2, much larger and more abrupt changes of β can be
achieved than with conventional solvents. As a consequence,
micro– and nanoparticulate materials with a narrow size distrib-
ution, unachievable through conventional processes, can be
prepared without problem. Further, it is often possible to pre-
pare, at a large scale, materials with a specific internal structure
Figure 2. Schematic representation of different preparation strategies
to obtain nanoparticulate materials.
Figure 3. Trace A: qualitative supersaturation profile corresponding to a
crystallization process where nucleation phenomena are dominant
over crystal growth. Trace B: qualitative supersaturation profile corre-
sponding to a crystallization process where crystal growth is dominant
over nucleation.
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(polymorph, nanostructured composite material, porosity, de-
gree of crystallinity, etc.) unachievable by traditional methods.
Moreover, in these procedures, precipitation occurs in a non-
oxidising atmosphere, and without the need for the application
of high shear forces. Hence, these procedures are particularly
suited to the processing of thermally, chemically or physically
unstable materials, such as biological compounds, chemical
intermediates and pharmaceuticals.
Precipitation technologies using cCO2 hold a great deal of
promise in the pharmaceutical industry, which is currently fac-
ing the challenge of drug formulation involving active ingredi-
ents or diagnostic agents with low solubilities, high toxicities,
low stabilities, and short in vivo half-lives. Some potential appli-
cations of these new particle engineering methodologies in the
pharmaceutical industry include:
– Generation of micro– and nanosized drug particles to en-
hance dissolution and therefore bioavailability of sparingly
water-soluble or insoluble drugs.
– Encapsulation of proteins, peptides, vaccines and toxic di-
agnostic agents.
– Targeted delivery of biological or diagnostic agents.
– Parenteral formulations (e.g. injectable) applications.
– Metered dose and dry powder inhaler applications.
There are various precipitation processes involving com-
pressed CO2, leading to different particles in terms of size,
shape, and morphology, and offering various possible solu-
tions to the different problems faced, and allowing the prepara-
tion of various forms or formulations of any given drug or diag-
nostic agent [19,20]: dry inhalable powder, nanoparticle
suspension, microspheres or microcapsules of the drug em-
bedded in a carrier, drug-impregnated excipient or matrix, etc.
As summarized in Table 1, these precipitation processes can
be classified in three different groups according to the solvating
behavior of the CO2 in the process: as a solvent, as an anti-sol-
vent, or as a co-solvent. Next, we briefly describe the most sig-
nificant methodologies of these three categories, their advan-
tages and limitations. 
Rapid expansion of supercritical solutions (RESS) – CO2 as
a solvent
The RESS process involves the dissolution of the solute to pre-
cipitate in cCO2, generally under supercritical conditions, fol-
lowed by the rapid expansion of the resulting solution to at-
mospheric pressure through a nozzle. During the expansion,
the density and the solvent power of the cCO2 decreases dra-
matically, resulting in a high degree of solute supersaturation
(see trace A in Figure 3) and subsequent precipitation of solute
particles free of residual solvents. As can be inferred from the
SEM images of naproxen in Figure 4, the RESS procedure has
found success in the preparation of micro– and nanosized drug
actives and drug carriers such as, naproxen [21], carba-
mazepine [22], griseofulvin [23], phytosterol [24], ibuprofen
[21], nifedipine [25] or poly(L-lactic acid) (L-PLA) [26]. 
The particle shape, size distribution, and crystalline pattern
of the final materials can be tuned by playing on the process
parameters (atomization pressure and temperature, and fluid
velocity through the nozzle) and equipment design (nozzle type
and dimensions, and atomization chamber dimensions).
Nanostructured microspheres of drug or contrast agent em-
bedded in an excipient for controlled-release delivery can be
prepared, on the condition that both the active substance and
the carrier are soluble in cCO2. For example, Kim et al. have
used the RESS method to coprecipitate poly(l-lactic acid) 
(L-PLA), as drug-carrier, with the antiinflamatory naproxen [27].
Although RESS is a simple and effective method to produce
micro– and nanoparticulate materials, with a relatively narrow
particle size distribution, the major limitation of this process is
the low solubility of many materials (e.g. polymers, polar mole-
cules) in pure cCO2. A large amount of fluid is needed to pro-
duce a small yield. Frequently, RESS is therefore a compara-
tively costly technique.
Gas Antisolvent (GAS) – CO2 as an anti-solvent
Whereas the low solubility in cCO2 of a large number of thera-
peutics and contrast agents for diagnosis has a negative im-
pact on the large-scale production of micronized particles us-
ing the RESS technique, it can be turned into an advantage
Figure 4. RESS processed naproxen nanoparticles (from ref. [21])
Table 1. Major «bottom-up» precipitation procedures using compressed CO2 in order to obtain micro– and nano-particulate pharmaceutical materials.
CO2 solvation Processable Material/CO2 Working Stirring Use of organic
behavior material ratio pressures requirements Scale up solvents
RESS Solvent Apolar Very low > 20MPa No Difficult No
GAS Anti-solvent Apolar/polar High 5–10MPa Yes Favourable Yes
ASES Anti-solvent Apolar/polar Low 6–30MPa No Difficults Yes
DELOS Co-solvent Apolar/polar High 5–10MPa No Favourable Yes
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when cCO2 is used as an antisolvent. The ability of CFs, such
as cCO2, to dissolve and expand organic solvents, thus lower-
ing their solvent power, allows the use of cCO2 for the precipi-
tation of micro– and nanosized pharmaceutics from organic
solutions. Compressed fluids are characterized by densities in-
termediate to gases and liquids. As well as this, CFs have a
negligible surface tension between the liquid and vapour phas-
es close to the critical point, and allow solutes to exhibit rela-
tively high diffusivities (with respect to the solvent density).
These physical properties in combination allow for the genera-
tion of extremely small uniform particulate materials due to the
unusually high supersaturation concentrations that can be in-
duced. The favourable transport properties of CFs, and the ex-
istence of a homogeneous phase in situ, allow for the rapid re-
moval of trace amounts of organic solvent. The Gas Antisolvent
(GAS) [28] process and the Aerosol Solvent Extraction System
(ASES) [29,30] are two different high pressure crystallization
techniques where the CO2 behaves as an anti-solvent. In the
GAS process, shown schematically in Figure 5 left, a volume of
liquid solution of the compound to crystallize is expanded sev-
eral-fold by mixing it with cCO2. This expansion produces a de-
crease of the solvent power, the solution becomes supersatu-
rated, and the solute precipitates as finely divided particles. 
As is illustrated in Figure 5 right, in the ASES process, an or-
ganic solution of the compound to crystallize is sprayed
through a nozzle, as fine droplets, into a vessel pressurized
with cCO2. In this process the CO2 diffuses into the sprayed
droplets causing a rapid expansion of the solvent, decreasing
its solvating capacity and therefore forcing the solute to precip-
itate or crystallize as particles. «Engineering» new types of par-
ticles with different morphologies has been achieved with a
wide range of molecules, leading to nanoparticles (50–500nm),
microparticles (0.5–5µm), or empty «balloons». This permits a
very significant increase in the bioavailability of sparingly water-
soluble drugs, as well as the preparation of drugs with a narrow
particle size distribution suitable for pulmonary delivery. More-
over, microspheres of a drug embedded in an excipient for
controlled-release delivery can be prepared by these process-
es, without the limitations encountered with the RESS process,
because most active substances and carriers can be easily
dissolved in an organic solvent or an appropriate combination
of organic solvents. There are several systems of pharmaceuti-
cal interest that have been shown to be procesable through
cCO2 antisolvent techniques. Indeed, these techniques have
been used for the straightforward production of micro– and
nanoparticulate drugs, as well as for the formation of
drug/polymer micro-composites [20]. For instance, the ASES
technique has been assessed for the production of micronized
steroids for lung delivery. Budesonide, triamcinolone, ace-
tonide, fluticasone-17-propionate, prendisolone, and flu-
nisolide were all precipitated with average particle sizes of less
than 5µm [31]. Insulin, lysozyme, albumin, and recombinant
human DNase are examples of proteins that have been precip-
itated using cCO2 antisolvent techniques [32]. All have been
precipitated in the form of microparticles. Particle size reduc-
tion of proteins with compressed fluids can produce smaller
particles than spray and freeze-drying techniques while pre-
serving enzymatic activity [33]. Mammucari et al. have co-pre-
cipitated cyclodextrins (CDs) with a drug through the ASES
process, in order to improve their stability, solubility, dissolution
rates and reducing side effects [34]. The small particle size they
achieved makes the application of ASES potentially suitable
and advantageous for systems containing CDs in which the
particle size is an important aspect. Another example of co-
precipitation using CFs antisolvent techniques, is the encapsu-
lation of insulin with PLA and PEG/PLA in nanospheres, in the
range of 400–600nm, that Elvassore et al. have performed us-
ing the GAS technique [35]. Rantakyla et al. made an estimate
of the cost of cCO2 antisolvent precipitation on the industrial
scale. This cost analysis suggests that the use of cCO2 antisol-
vent precipitation should be considered only for high-value-
added products. Although the versatility of the process does
allow the unit to be used for the processing of different materi-
als, in its current operation, CFs antisolvent precipitation is not
a continuous process because the collection of the product re-
quires the depressurization of the collecting chamber [36].
Depressurization of an Expanded Liquid Organic Solution
(DELOS) CO2 as co-solvent
We have developed a new precipitation procedure, called De-
pressurization of an Expanded Liquid Organic Solution (DE-
LOS) [37,38], where cCO2 is used for the straightforward pro-
duction of micron-sized and sub-micron-sized crystalline
particles from an organic solution. This process differs from the
other high-pressure techniques in that the cCO2 acts as co-
solvent being completely miscible, at a given pressure and
temperature, with the organic solution of the solute to be crys-
tallized [39]. The driving force behind precipitation in a DELOS
process is the large, rapid and extremely homogeneous tem-
perature decrease experienced by a CO2-expanded solution of
the compound to crystallize, when its is depressurized. 
The DELOS process comprises the following three steps,
which are schematized in Figure 6. 1) Dissolution of the solute
to be crystallized in a conventional organic solvent, at atmos-
pheric pressure and at a working temperature, TW. 2) Addition
of a CF (e.g. CO2) over the organic solution in order to obtain a
volumetric expanded liquid solution, at the working tempera-
ture (TW) and at a high working pressure (PW) containing a given
Figure 5. Schematic representation of two different configurations
used to perform CO2 antisolvent precipitation: Gas Antisolvent (GAS)
(left); Aerosol Solvent Extraction system (ASES).
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molar fraction of the cCO2 (XW), named as the working compo-
sition of cCO2. The solute concentration in this step (CW) must
remain below the saturation limit in the expanded mixture of the
organic solvent and the cCO2 (CSW); that is to say that the su-
persaturation ratio, βW, of the expanded solution must be less
than one. 3) Rapid reduction of the pressure of the liquid ex-
panded solution, from the working pressure to the atmospher-
ic one through a non-return valve. During this depressurization
process, the cCO2 evaporates from the expanded solution,
producing a large, fast and extremely homogeneous decrease
of the solution temperature down to the final temperature, TF.
As a consequence, there is a pronounced and homogeneous
increase of the supersaturation ratio, throughout the solution,
triggering the phenomenon of catastrophic nucleation and
causing the precipitation of sub-micron– or micron-sized crys-
talline particles with a narrow particle size distribution.
In a DELOS process, the extent of CO2 vaporization at any
point in the liquid solution is exactly the same. As a conse-
quence, the solution temperature decrease and the evolution
of the supersaturation profile are extremely uniform throughout
the system. This has important technological implications,
since there is no need for efficient stirring systems which would
otherwise be needed to avoid inhomogeneous solution cool-
ing, and prevent a precipitation with a wide particle size distrib-
ution and non-homogeneous internal structure. Moreover,
since precipitation in the DELOS process occurs far from equi-
librium conditions, it is possible to produce materials with an in-
ternal structure not achievable by thermodynamically-con-
trolled processes [40]. Compared to other high-pressure
crystallization techniques, such as RESS and ASES, the DE-
LOS process method requires only moderate operating pres-
sures, which is an important advantage when considering
scale-up and the economic evaluation of the process. The de-
sign of the process is simpler than that of other techniques with
cCO2. No stirring is required, in contrast with the GAS tech-
nique, because of the homogeneous cooling during the de-
pressurization stage [41]. Finally, the operation of the DELOS
process in a continuous mode is easier than the CF antisolvent
techniques, since in the former method the collection of the
precipitated material is performed at atmospheric conditions,
whereas in the later it should be done at high pressure. The
DELOS process has been demonstrated to be an efficient
high-pressure crystallization method for the straightforward
production of micron– and nano-sized pharmaceutical actives,
such as ibuprofen, acetaminophen, acetyl-salicylic acid,
naproxen, steroids, etc. with a high polymorphic purity [42],
and work is on-going, in order to test the feasibility of this new
method for the preparation of micro– and nanoparticulate
drug/polymer composites.
Recently we have developed a new efficient procedure
based on DELOS, for the preparation of drug nanoparticles
stabilized in an aqueous phase [43]. In the preparation of col-
loidal systems by precipitation procedures, the size and size
distribution of the dispersed nanoparticles is strongly depen-
dent on the homogeneity of the supersaturation level, at any
point of the liquid solution and at any time of the procedure. In
the DELOS-SUSP method, the cooling of the solution, which is
the precipitation driving force, takes place to the same extent
at any point of the solution, favoring the production of
nanosuspensions with a narrow-dispersed particle size distrib-
ution. As can be observed in Figure 7, using this technique we
have been able to prepare stable nanosuspensions of choles-
terol with a mean particle size of 100nm. 
The DELOS-SUSP technique has been shown to be effec-
tive for the preparation of aqueous nanosuspensions of differ-
ent non-water soluble polymeric excipients and pharmaceuti-
cal actives.
Conclusion
Precipitation techniques using compressed fluids are efficient
procedures for the preparation of micro– and nanostructured
materials with applications in drug-delivery and clinical diagno-
sis. These «bottom-up» preparation procedures have many
advantages compared to conventional processes, including
rapid one-step processing, moderate operating temperatures
(essential for thermally labile compounds), and control of parti-
cle size and material internal structure. Some of these tech-
niques, such as GAS, ASES and RESS, have been modified
for drug encapsulation, impregnation and coating, and others,
like DELOS, for the preparation of nanosuspensions of non-
soluble therapeutically active compounds. It has been demon-
strated that pharmaceutical materials, prepared by techniques
Figure 6. Steps of a DELOS process: (1) A liquid solution of the com-
pound to be crystallized is added to the autoclave. (2) Addition of CO2
produces a new expanded liquid solution which fills all the autoclave
volume at a given pressure, PW, and temperature, TW, giving rise to a
solution with a molar fraction of CO2 of XW. (3) Depressurization of the
expanded liquid solution through a valve leading to precipitation of
nano– or micron-sized particles, with a narrow size distribution.
Figure 7. a) Photographs of cholesterol in water suspensions prepared
by mixing methods (left two samples) and by the DELOS-SUSP proce-
dure (right sample). b) Laser light diffraction analysis of a cholesterol
nanosuspension in water, obtained through the DELOS-SUSP
method.
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with cCO2, are efficient for many drug delivery systems, such
as aerosol, and intravenous or subcutaneous delivery, be-
cause of the dramatic particle size reduction, as well as for oral
delivery, as a result of the significant improvement in dissolu-
tion rates of sparingly water soluble drugs. The main obstacle
to the application of CFs as solvent media in industrial
processes is the lack of fundamental studies accurately de-
scribing the phase behaviour of the multi-component systems
involved in the process. The practical implementation of pre-
cipitation procedures with CFs for fine-particle production on
the commercial scale requires predictability of product charac-
teristics. Therefore, understanding the influence of all relevant
process parameters on the size and shape of the particles
formed by these processes is important. However, with im-
proved understanding of current techniques and continued
innovation, it is foreseeable that the use of CFs for the pro-
cessing of pharmaceutical materials will soon become com-
mercially available.
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